Atıf İçin Kopyala
Cadirci K., Turkez H., Ozdemir O.
ACTA ENDOCRINOLOGICA-BUCHAREST, cilt.15, sa.1, ss.9-15, 2019 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
15
Sayı:
1
-
Basım Tarihi:
2019
-
Doi Numarası:
10.4183/aeb.2019.9
-
Dergi Adı:
ACTA ENDOCRINOLOGICA-BUCHAREST
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.9-15
-
Anahtar Kelimeler:
DPP-4 inhibitor, linagliptin, cytotoxicity, oxidative stress, genotoxicity, DPP-4 INHIBITORS, GLYCEMIC CONTROL, TYPE-2, SAFETY, TOLERABILITY, SITAGLIPTIN, MANAGEMENT, EFFICACY, THERAPY, STRESS
-
Atatürk Üniversitesi Adresli:
Evet
Özet
Background. Linagliptin (LNG) is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor that ameliorates blood glucose control of patients with type 2 diabetes, without developing hypoglycemic risk and weight gain with a good clinical and biological tolerance profile. To the best of our knowledge, its cytotoxic, genotoxic and oxidative effects have never been studied on any cell line.